Céline Louapre1, Sindhuja T Govindarajan1, Costanza Giannì1, Christian Langkammer1, Jacob A Sloane1, Revere P Kinkel1, Caterina Mainero2. 1. From the Athinoula A. Martinos Center for Biomedical Imaging (C. Louapre, S.T.G., C.G., C. Langkammer, C.M.), Charlestown, MA; Harvard Medical School (C. Louapre, C.G., C. Langkammer, C.M.), Boston, MA; Beth Israel Deaconness Medical Center (J.A.S.), Boston, MA; and Department of Neurosciences (R.P.K.), University of California San Diego, CA. 2. From the Athinoula A. Martinos Center for Biomedical Imaging (C. Louapre, S.T.G., C.G., C. Langkammer, C.M.), Charlestown, MA; Harvard Medical School (C. Louapre, C.G., C. Langkammer, C.M.), Boston, MA; Beth Israel Deaconness Medical Center (J.A.S.), Boston, MA; and Department of Neurosciences (R.P.K.), University of California San Diego, CA. caterina@nmr.mgh.harvard.edu.
Abstract
OBJECTIVES: Using quantitative T2* 7-tesla (7T) MRI as a marker of demyelination and iron loss, we investigated, in patients with relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), spatial and tissue intrinsic characteristics of cortical lesion(s) (CL) types, and structural integrity of perilesional normal-appearing cortical gray matter (NACGM) as a function of distance from lesions. METHODS: Patients with MS (18 RRMS, 11 SPMS), showing at least 2 CL, underwent 7T T2* imaging to obtain (1) magnitude images for segmenting focal intracortical lesion(s) (ICL) and leukocortical lesion(s) (LCL), and (2) cortical T2* maps. Anatomical scans were collected at 3T for cortical surface reconstruction using FreeSurfer. Seventeen age-matched healthy participants served as controls. RESULTS: ICL were predominantly located in sulci of frontal, parietal, and cingulate cortex; LCL distribution was more random. In MS, T2* was higher in both ICL and LCL, indicating myelin and iron loss, than in NACGM (p < 0.00003) irrespective of CL subtype and MS phenotype. T2* was increased in perilesional cortex, tapering away from CL toward NACGM, the wider changes being for LCL in SPMS. NACGM T2* was higher in SPMS relative to RRMS (p = 0.006) and healthy cortex (p = 0.02). CONCLUSIONS: CL had the same degree of demyelination and iron loss regardless of lesion subtype and disease stage. Cortical damage expanded beyond visible CL, close to lesions in RRMS, and more diffusely in SPMS. Evaluation of NACGM integrity, beyond focal CL, could represent a surrogate marker of MS progression.
OBJECTIVES: Using quantitative T2* 7-tesla (7T) MRI as a marker of demyelination and iron loss, we investigated, in patients with relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), spatial and tissue intrinsic characteristics of cortical lesion(s) (CL) types, and structural integrity of perilesional normal-appearing cortical gray matter (NACGM) as a function of distance from lesions. METHODS:Patients with MS (18 RRMS, 11 SPMS), showing at least 2 CL, underwent 7T T2* imaging to obtain (1) magnitude images for segmenting focal intracortical lesion(s) (ICL) and leukocortical lesion(s) (LCL), and (2) cortical T2* maps. Anatomical scans were collected at 3T for cortical surface reconstruction using FreeSurfer. Seventeen age-matched healthy participants served as controls. RESULTS: ICL were predominantly located in sulci of frontal, parietal, and cingulate cortex; LCL distribution was more random. In MS, T2* was higher in both ICL and LCL, indicating myelin and iron loss, than in NACGM (p < 0.00003) irrespective of CL subtype and MS phenotype. T2* was increased in perilesional cortex, tapering away from CL toward NACGM, the wider changes being for LCL in SPMS. NACGM T2* was higher in SPMS relative to RRMS (p = 0.006) and healthy cortex (p = 0.02). CONCLUSIONS: CL had the same degree of demyelination and iron loss regardless of lesion subtype and disease stage. Cortical damage expanded beyond visible CL, close to lesions in RRMS, and more diffusely in SPMS. Evaluation of NACGM integrity, beyond focal CL, could represent a surrogate marker of MS progression.
Authors: Natalia M Moll; Anna M Rietsch; Smitha Thomas; Amy J Ransohoff; Jar-Chi Lee; Robert Fox; Ansi Chang; Richard M Ransohoff; Elizabeth Fisher Journal: Ann Neurol Date: 2011-11 Impact factor: 10.422
Authors: J Cohen-Adad; J R Polimeni; K G Helmer; T Benner; J A McNab; L L Wald; B R Rosen; C Mainero Journal: Neuroimage Date: 2012-01-15 Impact factor: 6.556
Authors: Roberta Magliozzi; Owain W Howell; Cheryl Reeves; Federico Roncaroli; Richard Nicholas; Barbara Serafini; Francesca Aloisi; Richard Reynolds Journal: Ann Neurol Date: 2010-10 Impact factor: 10.422
Authors: Alexandra Seewann; Hugo Vrenken; Evert-Jan Kooi; Paul van der Valk; Dirk L Knol; Chris H Polman; Petra J W Pouwels; Frederik Barkhof; Jeroen J G Geurts Journal: Mult Scler Date: 2011-05-11 Impact factor: 6.312
Authors: Claudia F Lucchinetti; Bogdan F G Popescu; Reem F Bunyan; Natalia M Moll; Shanu F Roemer; Hans Lassmann; Wolfgang Brück; Joseph E Parisi; Bernd W Scheithauer; Caterina Giannini; Stephen D Weigand; Jay Mandrekar; Richard M Ransohoff Journal: N Engl J Med Date: 2011-12-08 Impact factor: 91.245
Authors: Ansi Chang; Susan M Staugaitis; Ranjan Dutta; Courtney E Batt; Kathryn E Easley; Anthony M Chomyk; V Wee Yong; Robert J Fox; Grahame J Kidd; Bruce D Trapp Journal: Ann Neurol Date: 2012-10-17 Impact factor: 10.422
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Valeria T Barletta; Elena Herranz; Costantina A Treaba; Russell Ouellette; Ambica Mehndiratta; Marco L Loggia; Eric C Klawiter; Carolina Ionete; Sloane A Jacob; Caterina Mainero Journal: Mult Scler Date: 2019-04-11 Impact factor: 6.312
Authors: Constantina A Treaba; Elena Herranz; Valeria T Barletta; Ambica Mehndiratta; Russell Ouellette; Jacob A Sloane; Eric C Klawiter; Revere P Kinkel; Caterina Mainero Journal: J Neurol Date: 2021-02-01 Impact factor: 4.849
Authors: D Damjanovic; P Valsasina; M A Rocca; M L Stromillo; A Gallo; C Enzinger; H E Hulst; A Rovira; N Muhlert; N De Stefano; A Bisecco; F Fazekas; M J Arévalo; T A Yousry; M Filippi Journal: AJNR Am J Neuroradiol Date: 2016-09-29 Impact factor: 3.825
Authors: Elena Herranz; Costanza Giannì; Céline Louapre; Constantina A Treaba; Sindhuja T Govindarajan; Russell Ouellette; Marco L Loggia; Jacob A Sloane; Nancy Madigan; David Izquierdo-Garcia; Noreen Ward; Gabriel Mangeat; Tobias Granberg; Eric C Klawiter; Ciprian Catana; Jacob M Hooker; Norman Taylor; Carolina Ionete; Revere P Kinkel; Caterina Mainero Journal: Ann Neurol Date: 2016-10-25 Impact factor: 10.422
Authors: Tobias Granberg; Qiuyun Fan; Constantina Andrada Treaba; Russell Ouellette; Elena Herranz; Gabriel Mangeat; Céline Louapre; Julien Cohen-Adad; Eric C Klawiter; Jacob A Sloane; Caterina Mainero Journal: Brain Date: 2017-11-01 Impact factor: 13.501
Authors: Gabriel Mangeat; Atef Badji; Russell Ouellette; Constantina A Treaba; Elena Herranz; Tobias Granberg; Céline Louapre; Nikola Stikov; Jacob A Sloane; Pierre Bellec; Caterina Mainero; Julien Cohen-Adad Journal: Hum Brain Mapp Date: 2018-02-06 Impact factor: 5.038